RiskSignalData.ai revenue, team size, customer count, churn, and more in 2026.

RiskSignalData.ai is creating the first B2B/B2C neuro-symbolic contradiction inference AI engine for veterinary pharmacovigilance - a new class of infrastructure designed to test whether veterinary drugs behave in the real world as pharma claimed they would in trials. No post-approval system currently checks that in veterinary medicine. In 2024, U.S. consumers spent over $150 billion on their pets. Over 70% of households own at least one. Yet no one can tell them whether the drugs used on those animals are safe and performing as promised. Every veterinary drug enters the market on the basis of narrow trials - limited species, small sample sizes, short observation windows, and sanitized testing conditions. Whether those claims hold up in the field remains an open question. The FDA’s Center for Veterinary Medicine is under-staffed, receives 45% of its funding from the very companies it regulates, and does not disclose whether or when a drug is under post-market review. Meanwhile: • The U.S. veterinary pharmaceutical market is projected to reach $22B by 2030 • $60B in private equity has flowed into vet chains since 2017 • The $70B U.S. veterinary service market is projected to grow further by 2030 Yet there is still no functioning post-approval drug safety infrastructure. RiskSignalData.ai is addressing that gap. We serve: • Veterinarians - with tools to protect animal lives and safeguard their own reputation, income, and license by identifying risk before it turns into harm • Pet owners - with the first-ever visibility into how safe drugs are • Liability insurers - with intelligence on portfolio-level safety collapse • Pet health insurers - with risk scoring and early alerts that reduce premium exposure • Lawyers - with precision litigation targeting based on contradiction patterns • Investors - PEGs and stakeholders - with early visibility into risks that could impact portfolio valuation or exit strategy